English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/170471
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Evaluation of the potential therapeutic benefits of macrophage reprogramming in Multiple Myeloma Running

AuthorsGutiérrez-González, A.; Martínez-Moreno, Mónica; Samaniego, Rafael ; Arellano-Sánchez, Nohemí ; Salinas-Muñoz, Laura; Relloso, Miguel; Valeri, Antonio; Martínez-López, Joaquín; Corbí, Angel L. ; Hidalgo, Andrés; García-Pardo, Angeles ; Teixidó, Joaquín ; Sánchez-Mateos, Paloma
Issue DateNov-2016
PublisherAmerican Society of Hematology
CitationBlood 128(18):2241-2252 (2016)
AbstractTumor-associated macrophages (TAM) are important components of the multiple myeloma (MM) microenvironment that support malignant plasma cell survival and resistance to therapy. It has been proposed that macrophages (MØ) retain the capacity to change in response to stimuli that can restore their antitumor functions. Here, we investigated several approaches to reprogram MØ as a novel therapeutic strategy in MM. First, we found tumor-limiting and tumor-supporting capabilities for monocyte-derived M1-like MØ and M2-like MØ, respectively, when mixed with MM cells, both in vitro and in vivo. Multicolor confocal microscopy revealed that MM-associated MØ displayed a predominant M2-like phenotype in the bone marrow of MM patient samples, and a high expression of the pro-M2 cytokine macrophage migration inhibitory factor (MIF). To reprogram the protumoral M2-like MØ present in MM toward antitumoral M1-like MØ, we tested the pro-M1 cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) plus blockade of the M2 cytokines macrophage colony-stimulating factor or MIF. The combination of GM-CSF plus the MIF inhibitor 4-iodo-6-phenyl-pyrimidine achieved the best reprogramming responses toward anM1profile, at both gene and protein expression levels, as well as remarkable tumoricidal effects. Furthermore, this combined treatment elicited MØ-dependent therapeutic responses in MM xenograftmousemodels, which were linked to upregulation ofM1and reciprocal downregulation of M2 MØmarkers. Our results reveal the therapeutic potential of reprogramming MØ in the context of MM.
Publisher version (URL)https://doi.org/10.1182/blood-2016-01-695395
URIhttp://hdl.handle.net/10261/170471
ISSN0006-4971
E-ISSN1528-0020
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
Gutierrez-Gonzalez-et-al-BLOOD_2016.pdf1,98 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.